Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
- “nsaid*”[All Fields] AND “ibd”[All Fields] AND “cancer*”[All Fields]
- ((nsaid*) AND (colorectal cancer) AND (ibd))
- ((aspirin) AND (colorectal cancer)) AND (ibd)
- ((inflammatory bowel disease) OR (ibd)) AND ((nsaid*) OR (non-steroidal anti-inflammatory drug*) OR (nonsteroidal anti-inflammatory drug*)) AND ((CRC) OR (colorectal cancer)) AND (meta-analysis[Filter] OR review[Filter] OR systematicreview[Filter])
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tavakoli, P.; Vollmer-Conna, U.; Hadzi-Pavlovic, D.; Grimm, M.C. A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Public Health Rev. 2021, 42, 1603990. [Google Scholar] [CrossRef] [PubMed]
- Sonnenberg, A. Age distribution of IBD hospitalization. Inflamm. Bowel Dis. 2010, 16, 452–457. [Google Scholar] [CrossRef] [PubMed]
- Feuerstein, J.D.; Cheifetz, A.S. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo. Clin. Proc. 2017, 92, 1088–1103. [Google Scholar] [CrossRef] [PubMed]
- Adams, S.M.; Bornemann, P.H. Ulcerative colitis. Am. Fam. Physician 2013, 87, 699–705. [Google Scholar]
- Brown, W.R.; Tayal, S. Microscopic colitis. A review. J. Dig. Dis. 2013, 14, 277–281. [Google Scholar] [CrossRef]
- Seyedian, S.S.; Nokhostin, F.; Malamir, M.D. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J. Med. Life 2019, 12, 113–122. [Google Scholar] [CrossRef]
- Baumgart, D.C.; Sandborn, W.J. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007, 369, 1641–1657. [Google Scholar] [CrossRef]
- Windsor, J.W.; Kaplan, G.G. Evolving Epidemiology of IBD. Curr. Gastroenterol. Rep. 2019, 21, 40. [Google Scholar] [CrossRef]
- Mak, W.Y.; Zhao, M.; Ng, S.C.; Burisch, J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol. 2020, 35, 380–389. [Google Scholar] [CrossRef]
- Alatab, S.; Sepanlou, S.G.; Ikuta, K.; Vahedi, H.; Bisignano, C.; Safiri, S.; Sadeghi, A.; Nixon, M.R.; Abdoli, A.; Abolhassani, H.; et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study. Lancet Gastroenterol. Hepatol. 2020, 5, 17–30. [Google Scholar] [CrossRef]
- Kaplan, G.G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 720–727. [Google Scholar] [CrossRef]
- Ott, C.; Schölmerich, J. Extraintestinal manifestations and complications in IBD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 585–595. [Google Scholar] [CrossRef]
- Kuźnicki, P.; Neubauer, K. Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse. J. Clin. Med. 2021, 10, 4623. [Google Scholar] [CrossRef]
- Hu, S.; Chen, Y.; Chen, Y.; Wang, C. Depression and Anxiety Disorders in Patients with Inflammatory Bowel Disease. Front. Psychiatry 2021, 12, 714057. [Google Scholar] [CrossRef]
- Dyson, J.K.; Rutter, M.D. Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk? World J. Gastroenterol. 2012, 18, 3839–3848. [Google Scholar] [CrossRef]
- Clarke, W.T.; Feuerstein, J.D. Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. World J. Gastroenterol. 2019, 25, 4148–4157. [Google Scholar] [CrossRef]
- Shah, S.C.; Itzkowitz, S.H. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2022, 162, 715–730. [Google Scholar] [CrossRef]
- Keller, D.S.; Windsor, A.; Cohen, R.; Chand, M. Colorectal cancer in inflammatory bowel disease: Review of the evidence. Tech. Coloproctol. 2019, 23, 3–13. [Google Scholar] [CrossRef]
- Axelrad, J.E.; Lichtiger, S.; Yajnik, V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J. Gastroenterol. 2016, 22, 4794–4801. [Google Scholar] [CrossRef]
- Nørregaard, R.; Kwon, T.H.; Frøkiær, J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Res. Clin. Pract. 2015, 34, 194–200. [Google Scholar] [CrossRef]
- Tremi, I.; Nowsheen, S.; Aziz, K.; Siva, S.; Ventura, J.; Hatzi, V.I.; Martin, O.A.; Georgakilas, A.G. Inflammation and oxidatively induced DNA damage: A Synergy leading to cancer development. In Cancer: Oxidative Stress and Dietary Antioxidants; Academic Press: Cambridge, MA, USA, 2021; pp. 131–147. [Google Scholar] [CrossRef]
- Gurpinar, E.; Grizzle, W.E.; Piazza, G.A. NSAIDs inhibit tumorigenesis, but how? Clin. Cancer Res. 2014, 20, 1104–1113. [Google Scholar] [CrossRef] [PubMed]
- Kaneko, N.; Kurata, M.; Yamamoto, T.; Morikawa, S.; Masumoto, J. The role of interleukin-1 in general pathology. Inflamm. Regen. 2019, 39, 12. [Google Scholar] [CrossRef] [PubMed]
- Grancher, A.; Michel, P.; Di Fiore, F.; Sefrioui, D. Aspirin and colorectal cancer. Bull. Cancer 2018, 105, 171–180. [Google Scholar] [CrossRef]
- Burn, J.; Sheth, H.; Elliott, F.; Reed, L.; Macrae, F.; Mecklin, J.-P.; Möslein, G.; McRonald, F.E.; Bertario, L.; Evans, D.G.; et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: A double-blind, randomised, placebo-controlled trial. Lancet 2020, 395, 1855–1863. [Google Scholar] [CrossRef]
- Guo, C.-G.; Ma, W.; Drew, D.A.; Cao, Y.; Nguyen, L.H.; Joshi, A.D.; Ng, K.; Ogino, S.; Meyerhardt, J.A.; Song, M.; et al. Aspirin Use and Risk of Colorectal Cancer Among Older Adults. JAMA Oncol. 2021, 7, 428–435. [Google Scholar] [CrossRef]
- Long, M.D.; Kappelman, M.D.; Martin, C.F.; Chen, W.; Anton, K.; Sandler, R.S. Role of Nonsteroidal Anti-Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J. Clin. Gastroenterol. 2016, 50, 152–156. [Google Scholar] [CrossRef]
- Din, F.V.N.; Theodoratou, E.; Farrington, S.M.; Tenesa, A.; Barnetson, R.A.; Cetnarskyj, R.; Stark, L.; Porteous, M.E.; Campbell, H.; Dunlop, M. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010, 59, 1670–1679. [Google Scholar] [CrossRef]
- Asano, T.K.; McLeod, R.S. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst. Rev. 2004, 2021, CD004079. [Google Scholar] [CrossRef]
- Terhaar Sive Droste, J.S.; Tuynman, J.B.; Van Dullemen, H.M.; Mulder, C.J. Chemoprevention for colon cancer: New opportunities, fact or fiction? Scand. J. Gastroenterol. Suppl. 2006, 41, 158–164. [Google Scholar] [CrossRef]
- Patel, P.; Gao, G.; Gulotta, G.; Dalal, S.; Cohen, R.D.; Sakuraba, A.; Rubin, D.T.; Pekow, J. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm. Bowel. Dis. 2021, 27, 236–241. [Google Scholar] [CrossRef]
- Hensley, A.; Beales, I.L. Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals 2015, 8, 512–524. [Google Scholar] [CrossRef]
- Aromataris, E.; Fernandez, R.; Godfrey, C.M.; Holly, C.; Khalil, H.; Tungpunkom, P. Summarizing systematic reviews: Methodological development, conduct and reporting of an umbrella review approach. Int. J. Evid. Based Healthc. 2015, 13, 132–140. [Google Scholar] [CrossRef]
- Kefalakes, H.; Stylianides, T.J.; Amanakis, G.; Kolios, G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or reality? Eur. J. Clin. Pharmacol. 2009, 65, 963–970. [Google Scholar] [CrossRef]
- Kvasnovsky, C.L.; Aujla, U.; Bjarnason, I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand. J. Gastroenterol. 2015, 50, 255–263. [Google Scholar] [CrossRef]
- Burr, N.E.; Hull, M.A.; Subramanian, V. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? World. J. Gastroenterol. 2016, 22, 3679–3686. [Google Scholar] [CrossRef]
- Abdalla, L.F.; Chaudhry Ehsanullah, R.; Karim, F.; Oyewande, A.A.; Khan, S. Role of Using Nonsteroidal Anti-Inflammatory Drugs in Chemoprevention of Colon Cancer in Patients with Inflammatory Bowel Disease. Cureus 2020, 12, e8240. [Google Scholar] [CrossRef]
- Cheng, Y.; Desreumaux, P. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J. Gastroenterol. 2005, 11, 309–314. [Google Scholar] [CrossRef]
- Chan, E.P.; Lichtenstein, G.R. Chemoprevention: Risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol. Clin. N. Am. 2006, 35, 675–712. [Google Scholar] [CrossRef]
- Bonovas, S.; Fiorino, G.; Lytras, T.; Nikolopoulos, G.; Peyrin-Biroulet, L.; Danese, S. Systematic review with meta-analysis: Use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017, 45, 1179–1192. [Google Scholar] [CrossRef]
- Margagnoni, G.; Pagnini, C.; Menasci, F.; Festa, S.; Delle Fave, G. Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: A methodological question. Curr. Clin. Pharmacol. 2014, 9, 84–90. [Google Scholar] [CrossRef] [PubMed]
- Qiu, X.; Ma, J.; Wang, K.; Zhang, H. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: A systematic review with meta-analysis. Oncotarget 2017, 8, 1031–1045. [Google Scholar] [CrossRef] [PubMed]
- van Staa, T.P.; Card, T.; Logan, R.F.; Leufkens, H.G. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: A large epidemiological study. Gut 2005, 54, 1573–1578. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Luo, Y.; Chen, T.; Zhang, K. Low-dose aspirin use and cancer-specific mortality: A meta-analysis of cohort studies. J. Public Health 2021, 43, 308–315. [Google Scholar] [CrossRef] [PubMed]
- Actis, G.C.; Pellicano, R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J. Gastrointest. Pharmacol. Ther. 2017, 8, 114–119. [Google Scholar] [CrossRef]
- Yamamoto, T.; Isono, A.; Mishina, Y.; Ebato, T.; Shirai, T.; Nakayama, S.; Nagasawa, K.; Abe, K.; Hattori, K.; Ishii, T.; et al. Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: Possible effect of rebamipide. J. Clin. Biochem. Nutr. 2010, 47, 27–31. [Google Scholar] [CrossRef]
- Angstadt, A.Y.; Hartman, T.J.; Lesko, S.M.; Muscat, J.E.; Zhu, J.; Gallagher, C.J.; Lazarus, P. The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: Haplotype associations and gene–environment interactions. Genes Chromosom. Cancer 2014, 53, 454–466. [Google Scholar] [CrossRef]
- Penn State College of Medicine (n.d.). The IBM Marketscan Commercial Claims and Encounters Database. Center for Applied Studies in Health Economics. Available online: https://cashe.psu.edu/resources/marketscan/ (accessed on 7 November 2022).
- TriNetX. Penn State Clinical and Translational Science Institute. 4 August 2022. Available online: https://ctsi.psu.edu/research-support/trinetx/ (accessed on 7 November 2022).
- Zappavigna, S.; Cossu, A.M.; Grimaldi, A.; Bocchetti, M.; Ferraro, G.A.; Nicoletti, G.F.; Filosa, R.; Caraglia, M. Anti-Inflammatory Drugs as Anticancer Agents. Int. J. Mol. Sci. 2020, 21, 2605. [Google Scholar] [CrossRef]
- Sibbald, B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004, 171, 1027–1028. [Google Scholar] [CrossRef]
- NCBI Bookshelf (n.d.). Celecoxib. StatPearls. Available online: https://www.ncbi.nlm.nih.gov/books/NBK535359/ (accessed on 7 November 2022).
- Thompson, P.A.; Ashbeck, E.L.; Roe, D.J.; Fales, L.; Buckmeier, J.; Wang, F.; Bhattacharyya, A.; Hsu, C.-H.; Chow, S.H.H.; Ahnen, D.J.; et al. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J. Natl. Cancer Inst. 2016, 108, djw151. [Google Scholar] [CrossRef]
- Kraus, S.; Naumov, I.; Arber, N. COX-2 active agents in the chemoprevention of colorectal cancer. Prospect. Chemoprevention Color. Neoplasia 2013, 191, 95–103. [Google Scholar] [CrossRef]
- He, P.; Yang, C.; Ye, G.; Xie, H.; Zhong, W. Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: A meta-analysis. Color. Dis. 2019, 21, 417–426. [Google Scholar] [CrossRef]
- Church, R.D.; Yu, J.; Fleshman, J.W.; Shannon, W.D.; Govindan, R.; McLeod, H.L. RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. Br. J. Cancer 2004, 91, 1015–1018. [Google Scholar] [CrossRef]
- Ornelas, A.; Zacharias-Millward, N.; Menter, D.G.; Davis, J.S.; Lichtenberger, L.; Hawke, D.; Hawk, E.; Vilar, E.; Bhattacharya, P.; Millward, S. Beyond cox-1: The effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017, 36, 289–303. [Google Scholar] [CrossRef]
- Yan, S.L.; Russell, J.; Harris, N.R.; Senchenkova, E.Y.; Yildirim, A.; Granger, D.N. Platelet abnormalities during colonic inflammation. Inflamm. Bowel Dis. 2013, 19, 1245–1253. [Google Scholar] [CrossRef]
- Rigas, B. Novel agents for cancer prevention based on nitric oxide. Biochem. Soc. Trans. 2007, 35, 1364–1368. [Google Scholar] [CrossRef]
- Williams, J.L.; Borgo, S.; Hasan, I.; Castillo, E.; Traganos, F.; Rigas, B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: Implications for colon cancer chemoprevention. Cancer Res. 2001, 61, 3285–3289. [Google Scholar]
- Fiorucci, S.; Antonelli, E.; Burgaud, J.L.; Morelli, A. Nitric oxide-releasing NSAIDs: A review of their current status. Drug Saf. 2001, 24, 801–811. [Google Scholar] [CrossRef]
- Gao, J.; Liu, X.; Rigas, B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 2005, 102, 17207–17212. [Google Scholar] [CrossRef]
- Rolando, B.; Lazzarato, L.; Donnola, M.; Marini, E.; Joseph, S.; Morini, G.; Pozzoli, C.; Fruttero, R.; Gasco, A. Water-soluble nitric-oxide-releasing acetylsalicylic acid (ASA) prodrugs. ChemMedChem 2013, 8, 1199–1209. [Google Scholar] [CrossRef]
- Tashima, K.; Fujita, A.; Umeda, M.; Takeuchi, K. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Life Sci. 2000, 67, 1639–1652. [Google Scholar] [CrossRef] [PubMed]
- Wallace, J.L.; Zamuner, S.R.; McKnight, W.; Dicay, M.; Mencarelli, A.; del Soldato, P.; Fiorucci, S. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G76–G81. [Google Scholar] [CrossRef]
- Yeh, R.K.; Chen, J.; Williams, J.L.; Baluch, M.; Hundley, T.R.; Rosenbaum, R.E.; Kalala, S.; Traganos, F.; Benardini, F.; del Soldato, P.; et al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: A general pharmacological property? Biochem. Pharmacol. 2004, 67, 2197–2205. [Google Scholar] [CrossRef] [PubMed]
- Full Text View—ClinicalTrials.gov (n.d.). Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT00331786?term=nitric%2Boxide%2Baspirin&recrs=e&draw=2&rank=3 (accessed on 14 November 2022).
- Nan, H.; Hutter, C.M.; Lin, Y.; Jacobs, E.J.; Ulrich, C.M.; White, E.; Baron, J.A.; Berndt, S.I.; Brenner, H.; Butterbach, K.; et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 2015, 313, 1133–1142. [Google Scholar] [CrossRef] [PubMed]
- Chan, S.S.M.; Luben, R.; Bergmann, M.M.; Boeing, H.; Olsen, A.; Tjonneland, A.; Overvad, K.; Kaaks, R.; Kennedy, H.; Khaw, K.-T.; et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: A European prospective cohort study. Aliment. Pharmacol. Ther. 2011, 34, 649–655. [Google Scholar] [CrossRef]
- Ananthakrishnan, A.N.; Higuchi, L.M.; Huang, E.S.; Khalili, H.; Richter, J.M.; Fuchs, C.S.; Chan, A.T. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: A cohort study. Ann. Intern. Med. 2012, 156, 350–359. [Google Scholar] [CrossRef]
- Moninuola, O.O.; Milligan, W.; Lochhead, P.; Khalili, H. Systematic review with meta-analysis: Association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment. Pharmacol. Ther. 2018, 47, 1428–1439. [Google Scholar] [CrossRef]
- Berg, D.J.; Zhang, J.; Weinstock, J.V.; Ismail, H.F.; Earle, K.A.; Alila, H.; Pamukcu, R.; Moore, S.; Lynch, R.G. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002, 123, 1527–1542. [Google Scholar] [CrossRef]
Author(s) | Title | Year | Conclusions |
---|---|---|---|
Eaden | Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease | 2003 | There is not enough data to conclude that 5-ASA is an effective chemopreventative agent for CRC in IBD patients. |
Ryan et al. | Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow | 2003 | 5-ASAs provide protection against CRC and could be used in the general population and IBD patients |
Cheng and Desreumaux | 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease | 2005 | 5-ASA is a safe and effecting chemopreventative agent for IBD patients, but more studies, preferably randomized control trials, are needed to further assess the use of 5-ASA. |
Giannini et al. | 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for ‘best evidence’? | 2005 | Long term IBD treatment with 5-ASAs shows CRC prevention, and the use of it as a chemopreventative agent for IBD patients should be prioritized. |
Van Staa et al. | 5-Aminoalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study | 2005 | The consistent use of 5-ASAs over a long duration of time can reduce CRC risk in IBD patients. |
Velayos et al. | Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies | 2005 | There is a protective relationship between 5-ASAs and CRC for patients with UC. |
Chan and Lichtenstein | Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease | 2006 | 5-ASA compounds have been well-studied and show a dose of 1.2 g/d is likely effective for CRC prevention in DC and UC. |
Munkholm et al. | Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminoalicylates | 2006 | The risk of colorectal neoplasia can be reduced with use of 5-ASAs, although dosing suggestions are not stated. There is limited information on prospective clinical trials. |
Rubin et al. | Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update | 2008 | There are still gaps in research surrounding 5-ASA as chemoprevention for patients with IBD, although there does appear to be promising results. |
Droste et al. | Chemoprevention for colon cancer: New opportunities, fact or fiction? | 2009 | More studies need to investigate long-term use of 5-ASA for chemoprevention, as it is the primary maintenance medication. Selective COX-2 inhibitors could provide effective chemoprevention with minimal GI-toxicity. |
Herfarth | The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis | 2012 | 5-ASAs should not be used solely for chemoprevention of CRC in IBD patients |
Margagnoni et al. | Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question | 2014 | 5-ASAs can decrease incidence of CRC and are an ideal chemopreventative candidate for IBD patients |
O’Connor et al. | Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis | 2015 | When mesalamine is administered at greater than 1.2 g per day, there is a protective effect against the development of colorectal neoplasia. |
Burr et al. | Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? | 2016 | NA-NSAIDs and aspirin are mechanistically promising for the use of chemoprevention in IBD, but there is limited clinical evidence to make that conclusion. |
Bonovas et al. | Systematic review with meta-analysis: use of 5 aminosalicyclates and risk of colorectal neoplasia in patients with inflammatory bowel disease | 2017 | 5-ASAs have been shown to significantly reduce the risk of colorectal neoplasia, only in patients with UC. |
Qui et al. | Chemopreventative effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis | 2017 | 5-ASA is more effective at reducing the risk of CRC in patients with UC than CD. A dose greater than 1.2 g per day is most protective. |
Abdalla et al. | Role of Using Nonsteroidal Anti-Inflammatory Drugs in Chemoprevention of Colon Cancer in Patients with Inflammatory Bowel Disease | 2020 | The long-term use of NSAIDs is necessary to provide a protective effect, but patients can be at risk for negative health outcomes. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Newman, P.; Muscat, J. Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review. Cancers 2023, 15, 1102. https://doi.org/10.3390/cancers15041102
Newman P, Muscat J. Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review. Cancers. 2023; 15(4):1102. https://doi.org/10.3390/cancers15041102
Chicago/Turabian StyleNewman, Peri, and Joshua Muscat. 2023. "Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review" Cancers 15, no. 4: 1102. https://doi.org/10.3390/cancers15041102